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Objective To determine the past-year prevalence rates and correlates of simultaneous co-ingestion of prescription stimulants and other
substances among US high school seniors.
Methods Nationally representative probability samples of US high school seniors were surveyed as a part of the Monitoring the Future
study. The sample consisted of ﬁve cohorts including a total of 12 431 high school seniors (modal age: 18 years) and represented a population
that was 53% female.
Results Among past-year nonmedical users of prescription stimulants (n= 835), the estimated prevalence of any past-year simultaneous co-
ingestion of prescription stimulants and other substances was 64.4%. The substances most commonly co-ingested with prescription stimu-
lants included marijuana (51.1%) and alcohol (48.4%). Nonmedical users who co-ingested prescription stimulants with other substances were
more likely to report non-oral routes of administration, recreational motives and greater subjective high when using prescription stimulants
than nonmedical users who did not co-ingest prescription stimulants with other substances.
Conclusions The majority of past-year nonmedical users of prescription stimulants reported simultaneous co-ingestion of prescription
stimulants and other substances. The ﬁndings indicate that co-ingestion of prescription stimulants and other substances is a pervasive behavior
among US adolescents who engage in nonmedical use of prescription stimulants and should be carefully considered in future clinical practice
and research. Copyright © 2014 John Wiley & Sons, Ltd.
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INTRODUCTION
The nonmedical use of prescription stimulants and
stimulant use disorders are most prevalent among
adolescents and young adults in the US, although these
behaviors have increased across all age groups over
the past two decades (Blanco et al., 2007; McCabe
et al., 2008; Johnston et al., 2013). For example, the
past-year nonmedical use of prescription stimulants in-
creased from 3.6% in 1992 to 11.1% in 2012 among
college students in the US (Johnston et al., 2013).
National, regional and case-report data document a
wide range of adverse consequences that can occur
as a result of simultaneous co-ingestion of
prescription stimulants with alcohol and other drugs
(Markowitz et al., 2000a, 2000b; Barrett and Pihl,
2002; Watson et al., 2004; McCabe et al., 2006;
SAMHSA, 2013a, 2013b). Data from the Drug Abuse
Warning Network indicate that emergency depart-
ment (ED) visits associated with nonmedical use of
attention-deﬁcit/hyperactivity disorder (ADHD)
stimulant medications often involve the simultaneous
use of other substances (SAMHSA, 2013a, 2013b).
Indeed, marijuana was the most common substance
simultaneously co-ingested with ADHD stimulant
medications among adolescents aged 15 to 17 years
involved in ED visits, while alcohol was the most
common substance simultaneously co-ingested with
ADHD stimulant medications among young adults
aged 18 to 25 years involved in ED visits (SAMHSA,
2013b). The estimated number of ED visits involving
the nonmedical use of prescription stimulants has
steadily increased among those 18 to 25years of age
(SAMHSA, 2013a, 2013b). For example, the number
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of ED visits involving ADHD stimulant medications in-
creased from 2131 in 2005 to 8148 in 2010, or 382%
(SAMHSA, 2013b).
The simultaneous co-ingestion of prescription medi-
cations and other psychoactive drugs is a behavior that
has been shown to increase the risk for substance use
disorders (Compton and Volkow, 2006; McCabe
et al., 2006). Despite the notable risks associated with
co-ingestion of prescription stimulants and other
psychoactive drugs, there is surprisingly little epidemi-
ological research directed at the prevalence of and
characteristics associated with the co-ingestion of non-
medical use of prescription stimulants and other drugs
among adolescents (Collins et al., 1998; Compton and
Volkow, 2006; Earleywine and Newcomb, 1997). A
few college-based studies have shown that the majority
of nonmedical users of prescription stimulants have
co-ingested prescription stimulants and other psycho-
active drugs (Barrett et al., 2005; McCabe et al.,
2006; Olthuis et al., 2013). To date, there have been
no national epidemiological studies that examine co-in-
gestion of prescription stimulants and other drugs
among secondary school students. Based on these gaps
in the existing literature, the main objectives of this
study were to identify the prevalence and correlates of
past-year co-ingestion of prescription stimulants and
other drugs in a national sample of high school seniors
in the US.
METHODS
Study design
The Monitoring the Future (MTF) study annually
surveys a cross-sectional, nationally representative
sample of high school seniors in approximately 135
public and private high schools in the coterminous
US (Johnston et al., 2013). The MTF study uses a
multi-stage sampling procedure: In stage 1, geographic
areas or primary sampling units are selected; in stage 2,
schools within primary sampling units are selected
(with probability proportionate to class size); and in
stage 3, students within schools are selected. Because
so many questions are included in the MTF study,
much of the questionnaire content is divided into six
different questionnaire forms that are randomly distrib-
uted. This approach results in six virtually identical
subsamples. The data collected from seniors receiving
Form 1 from 2002 to 2006 were used in this study
because these MTF surveys contained the most recent
questions regarding co-ingestion of prescription stimu-
lants and other substances in a national sample. The
student response rates for high school seniors ranged
from 82% to 83% for these cohorts. The school partic-
ipation rates ranged from 97% to 99% for these cohorts
for either originally sampled schools or replacement
schools. Additional details about the MTF design and
methods are available elsewhere (Johnston et al.,
2013). Approval was granted for this study by the
University of Michigan Institutional Review Board
Health Sciences.
Measures
The MTF study assesses demographic characteristics
such as sex, race, geographical region and substance
use behaviors.
Nonmedical use of prescription stimulants was
assessed with a series of items asking respondents on
how many occasions (if any) they used prescription
stimulants on their own, without a doctor’s orders
(e.g., Ritalin® and Dexedrine®). Respondents were
asked about nonmedical use of prescription stimulants
in the past 12months. The response scale ranged from
(1) no occasions to (7) 40 or more occasions.
Simultaneous co-ingestion of prescription stimulants
and other substances was measured with four items
focused on the number of times prescription stimulants
were used nonmedically at the same time as the
following substances so that the effects overlapped:
alcohol, marijuana, LSD and hallucinogens other than
LSD. The response scale ranged from (1) not at all to
(5) every time for each of the four items.
Drunkenness was measured using the following
item: “On how many occasions (if any) have you been
drunk or very high from drinking alcoholic beverages
during the last 12months?” The response scale was
the same as for nonmedical use of prescription
stimulants.
Cigarette use was measured using the following
item: “How frequently have you smoked cigarettes
during the past 30days?” The response scale was (1)
none, (2) less than 1 cigarette per day, (3) 1–5 ciga-
rettes per day, (4) about ½ pack per day, (5) about 1
pack per day, (6) about 1½ packs per day and (7) 2
or more packs per day.
Marijuana use was measured using the following
item: “On how many occasions (if any) have you used
marijuana during the last 12months?” The response
scale was the same as for nonmedical use of prescrip-
tion stimulants.
Other drug use—including LSD, psychedelics other
than LSD, cocaine and heroin—was measured with
the following question for each drug: “On how many
occasions (if any) have you used [SPECIFIED DRUG
CLASS]…during the last 12months?” The response
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scale was the same as for nonmedical use of prescrip-
tion stimulants.
Nonmedical use of other prescription medications—
including opioids, sedatives and tranquilizers—was
measured with the following question for each medica-
tion class: “On how many occasions (if any) have you
used [SPECIFIED DRUG CLASS]…during the last
12months?” The response scale was the same as for
nonmedical use of prescription stimulants.
Routes of administration for nonmedical use of pre-
scription stimulants were assessed with four items that
asked which methods respondents used for taking pre-
scription stimulants (mark all that apply). The binary
items included the following: (1) smoking; (2) injec-
tion; (3) orally (by mouth); and (4) other.
Social contexts of nonmedical use of prescription
stimulants were assessed by asking respondents the
locations they used prescription stimulants. The list
of locations included but was not limited to the follow-
ing: (1) at a party.
Motives for nonmedical use of prescription stimu-
lants were assessed by asking respondents who
reported nonmedical use to indicate the most important
reasons for nonmedical use (mark all that apply). The
list of binary items included but was not limited
to the following: (1) to feel good or get high; (2) to
increase the effects of some other drugs; and (3) to
decrease (offset) the effects of some other drugs.
Subjective high associated with nonmedical use of
prescription stimulants was measured with an item that
asked nonmedical users in the past 12months how
high they usually get when they use prescription stim-
ulants. The response scale for these items ranged from
(1) not at all high to (4) very high.
Data analysis
The MTF study provides survey weights for
responding cases in each of its public-use data ﬁles,
and these weights were used in all analyses to ensure
that estimates of population features were unbiased.
The estimated past-year prevalence rates of co-ingestion
involving nonmedical use of prescription stimulants
and other drugs—across subgroups deﬁned by demo-
graphic characteristics and substance use behaviors—
were computed using weighted cross-tabulations.
Design-adjusted Rao–Scott chi-square tests of homoge-
neity (Rao and Scott, 1984) and logistic regression
analyses (Heeringa et al., 2010) were conducted to
determine whether past-year simultaneous co-ingestion
involving nonmedical use of prescription stimulants
and other drugs was signiﬁcantly associated with other
substance use behaviors, including past-year drunken-
ness, smoking in the past 30days, past-year marijuana
use, past-year illicit drug use other than marijuana and
past-year nonmedical use of other prescription medica-
tions such as opioids, sedatives and tranquilizers. The
following three mutually exclusive groups were com-
pared in terms of other substance use behaviors in the
analyses: (1) no past-year nonmedical use of prescrip-
tion stimulants; (2) past-year nonmedical use of pre-
scription stimulants without simultaneous co-ingestion;
and (3) past-year nonmedical use of prescription stimu-
lants with simultaneous co-ingestion. The logistic regres-
sion models included sex, race/ethnicity, geographical
region, average grades, college intentions and frequency
of nonmedical use of prescription stimulants (Tables 4
and 5 only) as covariates based on their signiﬁcant bivar-
iate associations with dependent and independent vari-
ables used in the present study (e.g., the three-group
factor discussed earlier), nonmedical use of prescription
stimulants, and/or co-ingestion of prescription stimulants
and other drugs (McCabe et al., 2006; Johnston et al.,
2013; Chen et al., 2014).
The complex multi-stage sampling design used in
the MTF study resulted in the need to account for
effects of cluster sampling on variance estimates.
Estimated (linearized) variances of weighted esti-
mates were multiplied by an average MTF design
effect factor corrected for design effects because of
the cluster sampling prior to the construction of conﬁ-
dence intervals, and weighted Pearson chi-square
statistics were divided by this same design effect
factor (Rao and Scott, 1984) per the recommendation
of Johnston and colleagues (Johnston et al., 2013).
All statistical analyses were performed using com-
mands for the analysis of complex sample survey data
in the Stata 13.1 software (StataCorp, College Station,
TX, 2013).
RESULTS
Sample characteristics
There were 12431 individuals who completed Form
1 in the ﬁve cohorts between 2002 and 2006 during
the spring of their senior year, and these respon-
dents comprise the study sample. The full sample
represented a population of high school seniors that
was 52.7% women, 61.8% White, 10.1% African-
American, and 28.1% from other racial groups or
not specifying their race. The modal age of the
individuals in the sample was 18years of age.
Table 1 compares the sociodemographic characteris-
tics between the subpopulations of past-year
nonmedical users of prescription stimulants who co-
ingested other substances and past-year nonmedical
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users of prescription stimulants who did not co-ingest
other substances.
Simultaneous co-ingestion of prescription stimulants
and other drugs
The estimated prevalence of lifetime nonmedical use
of prescription stimulants among high school
seniors in the US between the years of 2002 and
2006 was 11.2% (SE=0.3%), while the prevalence
of past-year nonmedical use of prescription stimu-
lants was 7.3% (SE=0.3%). Among high school
seniors who reported past-year nonmedical use of
prescription stimulants (n=835), an estimated
34.0% used on 1 to 2 occasions, 20.5% used on 3
to 5 occasions, 13.6% used on 6 to 9 occasions
and 31.9% used on 10 or more occasions. The
majority of past-year nonmedical users of prescrip-
tion stimulants simultaneously co-ingested at least
one other substance while using prescription stimu-
lants. Indeed, the estimated prevalence of any past-year
simultaneous co-ingestion of prescription stimulants
and other substances (i.e., alcohol, marijuana, LSD
and other psychedelics) among past-year nonmedical
prescription stimulant users was 64.3% (SE=2.0%,
95% CI=60.4%, 68.3%). Among past-year nonmedical
users of prescription stimulants, the prevalence of
co-ingestion differed signiﬁcantly by race/ethnicity
(p<0.001), and a higher proportion of past-year
nonmedical users who also co-ingested was found
to be male compared with those who did not co-ingest
in the past year (Table 1). Signiﬁcant (p<0.05)
associations were also found between co-ingestion
and average grade point average as well as nonmedi-
cal stimulant use age of onset; those who co-ingested
in the past-year tended to have lower average grades
and earlier ages of onset.
The most prevalent forms of simultaneous co-
ingestion of prescription stimulants and other sub-
stances included marijuana (51.2%), alcohol (48.7%)
and non-LSD hallucinogens (9.2%). We examined
the estimated frequency of co-ingestion of prescription
stimulants and other substances among nonmedical
users of prescription stimulants (Table 2). Among
those past-year nonmedical users who co-ingested
prescription stimulants with other substances, we found
that co-ingestion was more likely to occur “a few times”
Table 1. Demographic characteristics among high school seniors in the US: past-year nonmedical users of prescription stimulants versus overall population
Demographic
characteristics
Overall population
of high school
seniors % (SE)
Past-year nonmedical
users of prescription stimulants
without co-ingestion % (SE)
Past-year nonmedical
users of prescription stimulants
with co-ingestion % (SE)
Non-co-ingestion versus
co-ingestion prescription
stimulant users p-value
Sex
Male 47.3 (0.6) 30.0 (3.4) 46.7 (2.7) F(1, 694) = 13.5, p< 0.001
Female 52.7 (0.6) 70.0 (3.4) 53.3 (2.7)
Race
White 61.8 (0.5) 73.9 (3.2) 71.1 (2.3) F(1.96, 1557.91) = 7.2, p< 0.001
Black 10.1 (0.3) 5.1 (1.6) 0.8 (0.4)
Other/not speciﬁed/missing 28.1 (0.5) 21.0 (3.0) 28.0 (2.3)
Geographical region
West 20.1 (0.4) 17.4 (2.7) 15.9 (1.9) NS
North Central/Midwest 24.8 (0.5) 19.3 (2.8) 26.0 (2.2)
South 34.8 (0.5) 42.6 (3.6) 38.1 (2.5)
Northeast 20.3 (0.4) 20.8 (2.7) 20.1 (1.9)
Urbanicity
Rural 46.7 (0.6) 47.0 (4.0) 51.0 (2.9) NS
Suburban/urban 53.3 (0.6) 53.0 (4.0) 49.0 (2.9)
Average grades
C or worse 18.4 (0.4) 18.6 (2.8) 27.7 (2.5) F(2, 1332.44) = 4.32, p< 0.05
B’s 46.8 (0.6) 49.5 (3.8) 50.6 (2.8)
A’s 34.8 (0.5) 31.9 (3.5) 21.7 (2.4)
College plans
Probably/deﬁnitely won’t 19.0 (0.5) 19.3 (3.2) 26.6 (2.6) NS
Probably/deﬁnitely will 81.0 (0.5) 80.7 (3.2) 73.4 (2.6)
Nonmedical use onset
6th or below – 0.0 (0.0) 2.4 (0.9) F(5.91, 66 676.49) = 2.64 p< 0.05
7th grade – 2.9 (1.5) 2.5 (0.9)
8th grade – 7.6 (2.6) 8.4 (1.7)
9th grade – 18.8 (3.9) 24.1 (2.7)
10th grade – 17.9 (3.5) 27.4 (2.8)
11th grade – 27.8 (3.9) 22.1 (2.4)
12th grade – 25.1 (3.8) 13.1 (2.0)
NS, non-signiﬁcant at the 0.05 level; –, not applicable.
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or “sometimes” as compared with “most times” or
“every time.” Among those past-year nonmedical
users who co-ingested prescription stimulants with
other substances and provided valid responses to all
of the co-ingestion questions, an estimated 42.4%
reported co-ingestion of one other substance, while
the majority (57.6%) reported co-ingestion of two or
more substances.
For past-year nonmedical prescription stimulant
users, we found that simultaneous co-ingestion of
any other substances was more prevalent among fre-
quent nonmedical users of prescription stimulants
(10 or more occasions in the past year) than non-
medical users who used less frequently (less than
10 occasions in the past year) (70.0% vs. 61.7%;
F(1, 11511)=3.71, p=0.05). For past-year marijuana
users, we found that simultaneous co-ingestion of
marijuana and prescription stimulants was more prev-
alent among frequent marijuana users (10 or more
occasions in the past year) than marijuana users who
used less frequently (less than 10 occasions in the
past year) (76.8% vs. 21.0%; F(1, 8357)=139.73,
p<0.01). For past-year alcohol users, we found that
simultaneous co-ingestion of alcohol and prescription
stimulants was more prevalent among frequent
alcohol users (10 or more occasions in the past year)
than alcohol users who used less frequently (less
than 10 occasions in the past year) (60.5% vs. 25.7%;
F(1, 4024)=57.14, p<0.01).
Simultaneous co-ingestion and other substance use
behaviors
The chi-square analyses revealed signiﬁcant associa-
tions between simultaneous co-ingestion of prescrip-
tion stimulants and other drugs and each substance
use behavior (p<0.001). As illustrated in Table 3,
multivariate logistic regression results reinforced the
bivariate ﬁndings; after adjusting for covariates found
to be signiﬁcantly associated with co-ingestion (sex,
race, geographical region, grade point average and
college plans), the odds of reporting substance use be-
haviors were considerably higher among individuals
who reported past-year nonmedical use of prescrip-
tion stimulants (both with and without co-ingestion)
compared with those who did not engage in past-year
nonmedical use of prescription stimulants (p<0.001).
In particular, the odds of reporting substance use
behaviors were substantially higher for those who
also reported co-ingestion.
Simultaneous co-ingestion and speciﬁc behaviors
related to prescription stimulants
The associations among simultaneous co-ingestion of
nonmedical use of prescription stimulants and other
drugs and speciﬁc behaviors related to the use of pre-
scription stimulants, such as route of administration,
social context, motives and subjective high, were also
examined using design-adjusted chi-square analyses,
revealing several strongly signiﬁcant associations
(p<0.001). As illustrated in Table 4, multiple logistic
regression results largely supported the bivariate ﬁnd-
ings; the odds of non-oral administration, using stimu-
lants at a party, using stimulants to get high or feel
good, using stimulants to increase or decrease the
effects of other drugs and using stimulants to get mod-
erately or very high were all signiﬁcantly greater
among those nonmedical users who co-ingested pre-
scription stimulants with other drugs as compared with
the odds of these behaviors for those nonmedical users
who did not report co-ingestion, after adjusting for
frequency of nonmedical use, sex, race, geographic
region, grade point average and college plans
(p<0.001). Notably, the odds of using prescription
stimulants to get high or feel good were more than
3.9 times greater among those nonmedical users who
co-ingested prescription stimulants with other drugs
as compared with those nonmedical users who did
not report co-ingestion (58.9% vs. 25.7%, AOR=3.9,
95% CI=2.5, 6.2, p<0.001).
We also examined the associations between the
number of substances co-ingested with prescription
stimulants and speciﬁc behaviors related to the use of
prescription stimulants, using design-adjusted Rao–
Scott chi-square analyses and logistic regression
analyses. We found that the odds of non-oral adminis-
tration, using stimulants at a party, using stimulants to
get high or feel good, using stimulants to increase or
decrease the effects of other drugs and using stimulants
Table 2. Co-ingestion of prescription stimulants and other substances among past-year nonmedical prescription stimulant users
Co-ingested substances (n)a Not at all % (SE) A few times % (SE) Sometimes % (SE) Most times % (SE) Every time % (SE)
Marijuana (n = 771) 48.8 (2.1) 16.9 (1.5) 15.0 (1.5) 9.5 (1.2) 9.9 (1.2)
Alcohol (n = 773) 51.3 (2.1) 21.1 (1.7) 15.2 (1.5) 5.8 (0.9) 6.6 (1.0)
Hallucinogens other than LSD (n = 679) 90.8 (1.2) 3.9 (0.7) 2.7 (0.7) 1.8 (0.6) 0.9 (0.3)
LSD (n = 753) 94.4 (1.0) 1.7 (0.5) 1.5 (0.5) 1.8 (0.7) 0.7 (0.3)
aThe (n) refers to the count of past-year nonmedical users of stimulants with valid data on each co-ingestion indicator.
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to get moderately or very high increased as a function
of the number of drugs co-ingested with prescription
stimulants (Table 5). For example, the odds of using
stimulants at a party were nearly 16 times greater
among those nonmedical users who co-ingested
prescription stimulants with two or more drugs as
compared with those nonmedical users who did not
report co-ingestion (AOR=15.7, 95% CI=8.6, 28.8,
p<0.001), after adjusting for frequency of nonmedical
use, sex, race, geographic region, grade point average
and college plans. Finally, we found that co-ingestion
involving prescription stimulants and two or more
drugs increased the odds of non-oral administration,
using stimulants at a party and using stimulants to
increase or decrease the effects of other drugs more
than co-ingestion with one drug (results not shown).
DISCUSSION
This was the ﬁrst national study to examine simulta-
neous co-ingestion involving prescription stimulants,
alcohol and other drugs among high school seniors in
the US. The ﬁndings indicate that over 6 in every 10
nonmedical stimulant users report the simultaneous
co-ingestion of prescription stimulants, alcohol and
other drugs in the previous year. A few prior investiga-
tions of college students found that the majority of
nonmedical users of prescription stimulants reported
co-ingestion of prescription stimulants and other drugs
in the past year (Barrett et al., 2005; McCabe et al.,
2006; Olthuis et al., 2013). The ﬁndings of this study
provide compelling evidence, based on a national
sample of high school seniors, that the majority of
past-year nonmedical users of prescription stimu-
lants have simultaneously co-ingested at least one
other drug while using prescription stimulants in
the past year.
We found that the most prevalent forms of simulta-
neous co-ingestion involving prescription stimulants
included marijuana or alcohol among high school
seniors in the US, which is consistent with past studies
among adolescents and young adults in North America
(Barrett et al., 2005; McCabe et al., 2006; Olthuis et al.,
2013; SAMHSA, 2013a, 2013b). The high rates of
co-ingestion involving prescription stimulants, mari-
juana and alcohol found among high school seniors
in the present study could be partially related to the
high prevalence and perceived availability of alcohol
and marijuana use among adolescents (Johnston
et al., 2013). For example, approximately 36% of
high school seniors have used marijuana in the past
12months, while over 80% indicate marijuana is
fairly easy or very easy to obtain (Johnston et al., Ta
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2013). Similarly, approximately 64% of high school
seniors have used alcohol in the past 12months, while
over 90% indicate alcohol is fairly easy or very easy
to obtain (Johnston et al., 2013). The present study
found that simultaneous co-ingestion was more likely
to occur “a few times” or “sometimes” as compared
with “most times” or “every time” among those
past-year nonmedical users who co-ingested prescrip-
tion stimulants with other substances. Past college-
based research found that the mean number of days
of simultaneous co-ingestion of nonmedical use of
prescription stimulants and alcohol was 3.3 days
(range 0–30days) in the past year (McCabe et al.,
2006). Interestingly, alcohol was used in greater
quantities when co-ingested with methylphenidate
than when alcohol was used alone by college students
(Barrett et al., 2006).
The simultaneous co-ingestion of prescription stim-
ulants and other psychoactive drugs can result in addi-
tional reinforcement, thereby increasing the addictive
potential (Compton and Volkow, 2006). Although the
causal mechanism(s) explaining why marijuana is the
drug most commonly co-ingested with prescription
stimulants requires additional investigation, there is
increasing evidence that cannabinoids modulate brain
reward systems closely involved in stimulant addiction
(Olière et al., 2013). A recent comprehensive review
regarding the interactions between the cannabinoid
system and stimulant use concluded that there are a
variety of ways in which cannabinoids (endogenous
and exogenous) may interact with psychostimulants
(Olière et al., 2013), which in turn could help to ex-
plain their co-ingestion among users. In addition to
the myriad of explanations provided by this compre-
hensive review, another highly relevant variable to con-
sider regarding the high rates of co-ingestion of
marijuana and stimulants is the low perceived conse-
quences associated with marijuana use among adoles-
cents (Johnston et al., 2013).
Regarding the substance that is the second most
commonly co-ingested substance with prescription
stimulants (i.e., alcohol) in this study, there is a
surprising lack of research available in the literature
to support or refute this ﬁnding. In fact, mechanisms
to explain the common occurrence and the apparent
appeal of co-ingestion of stimulants (more generally)
and alcohol is currently being investigated by the
National Institutes of Health (NIH). For example,
there is a recent funding opportunity announcement
(PA-13-339) from the NIH “…to promote research
to study the neurobiological and behavioral mecha-
nisms that might explain how alcohol and stimulants
interact at genetic, epigenetic, cellular, neurocircuitry
and behavioral levels to promote co-addiction.” One
aspect of stimulant and alcohol co-ingestion that
has been described in the literature is the possibility
of bidirectional vulnerability to the stimulant effects
of each substance. For example, Allen and Gabbay
(2013) discussed the idea that individuals who are
very responsive to the stimulant effects of amphet-
amines may be more responsive to the stimulant
effects of alcohol. In this original research report,
various potential mechanisms (e.g., personality traits
and reward sensitivity) are discussed, as well as a
call for further research (Allen and Gabbay, 2013).
Previous research has shown a wide array of acute
and long-term adverse consequences associated with
the simultaneous co-ingestion of prescription stimu-
lants and other drugs among adolescents and young
adults (Watson et al., 2004; McCabe et al., 2006;
SAMHSA, 2013a, 2013b). This study highlights that
substance use behaviors and health risks are more
prevalent among nonmedical users who co-ingest pre-
scription stimulants and other drugs relative to non-
medical users of prescription stimulants who do not
co-ingest and non-users. We found that nonmedical
users who co-ingested prescription stimulants with
other drugs were signiﬁcantly more likely than other
nonmedical users and non-users to engage in problem-
atic substance use behaviors, even after statistically
controlling for relevant covariates. Consistent with
recent national ﬁndings (SAMHSA, 2013b), we
found higher rates of adverse substance use behaviors
(e.g., non-oral administration) as a function of the
number of drugs co-ingested with prescription stimu-
lants. Lastly, research has demonstrated that the
simultaneous co-ingestion of nonmedical prescription
stimulants and alcohol among college students was
associated with lower grade point averages and
increased substance-related consequences (McCabe
et al., 2006; Egan et al., 2013). Taken together, these
ﬁndings reinforce the importance of distinguishing
nonmedical users who simultaneously co-ingest
prescription stimulants and other drugs from other
nonmedical users.
The present study extends existing knowledge by
identifying several behavioral correlates associated
with simultaneous co-ingestion of prescription stimu-
lants and other drugs, such as recreational social con-
texts, recreational motives, subjective high, frequent
nonmedical use of prescription stimulants, frequent
alcohol use, frequent marijuana use and non-oral
routes of administration. This study found that nearly
60% of nonmedical users who co-ingested were moti-
vated to get high or experiment and about 70% of non-
medical users who co-ingested used at parties; these
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results suggest that motives and social contexts for co-
ingestion are primarily recreational in nature. In
addition, the majority of nonmedical users who co-
ingested prescription stimulants and other drugs
reported non-oral routes of administration when using
prescription stimulants, relative to less than 14% of
nonmedical users who did not co-ingest. Taken
together, these behavioral correlates can potentially
serve as important signals to include in screening
efforts to detect nonmedical users of prescription
stimulants at the highest risk for developing sub-
stance use disorders in a clinical setting. In addition,
health professionals should be aware that adolescent
nonmedical users of prescription stimulants are
likely to be unaware of the stimulant’s potential
for interaction with other drugs or alternatively the
drug’s documented contraindications and precau-
tions. Many adolescents also tend to underestimate
the perceived harmfulness associated with the non-
medical use of prescription stimulants, and many
do not understand the dangerous interactions from
simultaneously co-ingesting prescription stimulants
and other substances (Johnston et al., 2013). For
example, passing out can be a protective mechanism
that stops people from drinking when they are
approaching potentially dangerous blood-alcohol
concentrations. However, using prescription stimu-
lants while drinking can potentially override this
mechanism, and this could lead to life-threatening
consequences.
The present study features several notable strengths,
such as the inclusion of a large national sample of high
school seniors. This study is the ﬁrst attempt to assess
simultaneous co-ingestion involving prescription stim-
ulants and other psychoactive drugs among high
school seniors in the US. Despite the strengths, there
were also several limitations that should be noted when
considering the implications of the ﬁndings. First, the
results cannot be generalized to all adolescents because
this sample only included high school seniors (modal
age: 18years) and did not include individuals who
had dropped out of school or were not present in
school on the day of survey administration. Second,
the data are subject to the potential response bias intro-
duced when assessing sensitive behaviors via self-
report surveys administered in a school setting. The
present study attempted to minimize these biases by
informing potential respondents that participation was
voluntary and assuring potential respondents that data
would remain conﬁdential (Johnston and O’Malley,
1985; Harrison and Hughes, 1997). Third, because
the present study represented secondary analyses, the
survey items in the MTF limited what variables could
be examined. For example, survey items were limited
to co-ingestion involving alcohol, marijuana, LSD
and hallucinogens other than LSD, and these items
did not specify the dose taken at each instance of co-
ingestion. Finally, the cross-sectional nature of the
study presented some limitations in terms of making
causal inferences; more comprehensive longitudinal
studies are needed to examine co-ingestion of prescrip-
tion stimulants and other drugs.
In summary, this study found that almost two-thirds
of past-year nonmedical users of prescription stimu-
lants simultaneously co-ingest prescription stimulants
and other psychoactive drugs. The ﬁndings of this
study have several important implications for preven-
tion and intervention efforts. Nonmedical users who
simultaneously co-ingest prescription stimulants and
other drugs are signiﬁcantly more likely than other
nonmedical users and non-users to engage in problem-
atic substance use behaviors. These ﬁndings indicate
the importance of identifying nonmedical users of pre-
scription stimulants who co-ingest prescription stimu-
lants and other drugs. Screening efforts to detect
adolescents who co-ingest prescription stimulants and
other drugs at an early stage would help identify a sub-
group of individuals who may beneﬁt from a more
comprehensive substance abuse assessment and treat-
ment. Prevention programs that provide information
and educate adolescents about blood-alcohol concen-
tration levels may not be relevant when adolescents
are combining prescription drugs with alcohol and
other drugs. Prevention and intervention efforts should
make adolescents aware of the potential consequences
associated with the co-ingestion of prescription stimu-
lants and other drugs.
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